RCT
Published: Apr 2016
ACE Report #8930
Ace Report Cover Metabolic Disorders

WCO-IOF 2016: Greater BMD increase after 1 year of romosozumab vesus teripratide

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy

Contributing Authors: C Libanati L Hyldstrup A Grauer P Lakatos HK Genant K Engelke TM Keaveny D Kendler S Goemaere JS Finkelstein B Langdahl J Malouf DB Crittenden E Jodar-Gimeno J Maddox FE Massari JF Molina MR Ulla

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Access conference website and list of abstracts.

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Explore some of our unlocked reports below!

Zoledronic acid increases BMD and prevents fracture risks in women with osteoporosis
Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women
Network meta-analysis of current drug options for the treatment of osteoporosis in men
Immediate effects on bone metabolism biomarkers noted with resistance training and walking
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.